AstraZeneca divests Atacand commercial rights to Cheplapharm
As per the terms of the deal, AstraZeneca received $250m from Cheplapharm. Credit: Nancy1007.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
